Canagliflozin: SGLT2 inhibitor for treating type 2 diabetes
Future Prescriber · 2013
DOI: 10.1002/fps.101 ↗Astratt
Abstract Canagliflozin is a sodium‐glucose transporter protein inhibitor under development for the treatment of type 2 diabetes mellitus; it reduces circulatory glucose by facilitating its urinary excretion. In this Drug profile, Richard Donnelly discusses the need for drugs with a mode of action independent of insulin and considers the efficacy and tolerability of canagliflozin in clinical trials, to date, as well as its potential place in management. Copyright © 2013 John Wiley & Sons, Ltd.
EUVIMED